company background image
NVS logo

Novartis NYSE:NVS Stock Report

Last Price

US$98.36

Market Cap

US$196.4b

7D

-3.6%

1Y

1.0%

Updated

13 Dec, 2024

Data

Company Financials +

NVS Stock Overview

Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More details

NVS fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance5/6
Financial Health4/6
Dividends5/6

Novartis AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Novartis
Historical stock prices
Current Share PriceCHF 98.36
52 Week HighCHF 120.92
52 Week LowCHF 92.35
Beta0.51
1 Month Change-5.30%
3 Month Change-14.96%
1 Year Change0.99%
3 Year Change14.51%
5 Year Change4.32%
Change since IPO1,035.47%

Recent News & Updates

Novartis: Time To Increase

Dec 13

Recent updates

Novartis: Time To Increase

Dec 13

What To Expect When Novartis Reports Q3 2024 Results

Oct 25

Why Novartis Deserves Your Attention After Q2 2024 Results

Jul 19

Novartis: Buy This Blue-Chip Dividend Stock On Sale Now

May 27

Novartis Looks To Get Back On Track With Q1 Earnings

Apr 19

New And Improved Novartis

Oct 30

Novartis: Better Margin Visibility Ex-Sandoz

Oct 06

Shareholder Returns

NVSUS PharmaceuticalsUS Market
7D-3.6%-3.3%-0.4%
1Y1.0%10.5%27.7%

Return vs Industry: NVS underperformed the US Pharmaceuticals industry which returned 10.5% over the past year.

Return vs Market: NVS underperformed the US Market which returned 27.7% over the past year.

Price Volatility

Is NVS's price volatile compared to industry and market?
NVS volatility
NVS Average Weekly Movement2.2%
Pharmaceuticals Industry Average Movement10.3%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: NVS has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: NVS's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199676,057Vas Narasimhanwww.novartis.com

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.

Novartis AG Fundamentals Summary

How do Novartis's earnings and revenue compare to its market cap?
NVS fundamental statistics
Market capUS$196.45b
Earnings (TTM)US$11.76b
Revenue (TTM)US$49.94b

16.7x

P/E Ratio

3.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NVS income statement (TTM)
RevenueUS$49.94b
Cost of RevenueUS$12.07b
Gross ProfitUS$37.87b
Other ExpensesUS$26.11b
EarningsUS$11.76b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 31, 2025

Earnings per share (EPS)5.88
Gross Margin75.83%
Net Profit Margin23.55%
Debt/Equity Ratio69.8%

How did NVS perform over the long term?

See historical performance and comparison

Dividends

3.7%

Current Dividend Yield

68%

Payout Ratio